Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$58.89M+225.63%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ramy Farid
- Sector
- Technology
- Industry
- Software - Application
- Employees
- 850
- Beta
- 1.69
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 3.56
Financials
Revenue
$58.89M+225.6%Net Income
$5.97MEBITDA
$7.35MFree Cash Flow
$63.38MEPS (diluted)
$0.08Shares Outstanding (diluted)
75.77M+1236.2%Operating Expenses
$73.98MCash & Debt
$413.74MRevenue by Segment (annual)
$582.51MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $255.87M | $-103.27M | $-1.41 |
| 2024 | $207.54M | $-187.12M | $-2.57 |
| 2023 | $216.67M | $40.72M | $0.57 |
| 2022 | $180.96M | $-149.19M | $-2.10 |
| 2021 | $137.93M | $-100.39M | $-1.43 |
| 2020 | $108.09M | $-24.46M | $-0.44 |
| 2019 | $85.54M | $-24.57M | $-0.41 |
| 2018 | $66.64M | $-28.43M | $-0.59 |
| 2017 | $55.69M | $-17.39M | $-3.07 |
Valuation
SDGRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
90+12.50%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·18d ago·Negative
Schrödinger: Company Creation Is Now The Real Drug Business Schrödinger, Inc. has undergone significant changes, including pipeline cuts and a strategic pivot away from solo clinical development. Despite software growth deceleration and pipeline setbacks, SDGR's financials improved with the Ajax sale and a stronger balance sheet. SDGR's net income turned positive in Q2 2026, aided by a $48.9M gain from Ajax and increased cash reserves to $418.8M.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsbusinesswire.com·35d ago·Neutral
Schrödinger to Present at Morgan Stanley Global Healthcare Conference NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation will take place on Monday, September 14, 2026 at 1:05 p.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event.…
View source ↗ - Newsbusinesswire.com·53d ago·Negative
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by …
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.66 per share
Typical surprise +28.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.08 vs $-0.41beat
- Tue, May 5$-0.81 vs $-0.56miss
- Wed, Feb 25$0.44 vs $-0.13beat
- Wed, Nov 5$-0.45 vs $-0.75beat
- Wed, Aug 6$-0.59 vs $-0.83beat
- Wed, May 7$-0.82 vs $-0.71miss
Estimates and results for SDGR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SDGR officers and directors.
- Bought
- —
- Sold
- $2.8m
0 trades
24 trades
- Akinsanya Karensold
- Akinsanya Karensold
- Jain Rachitsold
- Farid Ramysold
- Farid Ramysold
- Jain Rachitsold
- Herman Jennysold
- Herman Jennysold
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SDGR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.